ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学会発表・講演等
  2. ポスター発表

A novel chemogenetic agnoist "Deschloroclozapine" selectively visualizes and activates chemogenetic receptors in non-human primates

https://repo.qst.go.jp/records/81542
https://repo.qst.go.jp/records/81542
fc5ad68e-b615-4792-8299-d749e30199bc
Item type 会議発表用資料 / Presentation(1)
公開日 2021-01-05
タイトル
タイトル A novel chemogenetic agnoist "Deschloroclozapine" selectively visualizes and activates chemogenetic receptors in non-human primates
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_c94f
資源タイプ conference object
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 永井, 裕司

× 永井, 裕司

WEKO 915393

永井, 裕司

Search repository
宮川, 尚久

× 宮川, 尚久

WEKO 915394

宮川, 尚久

Search repository
堀, 由紀子

× 堀, 由紀子

WEKO 915395

堀, 由紀子

Search repository
南本, 敬史

× 南本, 敬史

WEKO 915396

南本, 敬史

Search repository
Nagai, Yuji

× Nagai, Yuji

WEKO 915397

en Nagai, Yuji

Search repository
Miyakawa, Naohisa

× Miyakawa, Naohisa

WEKO 915398

en Miyakawa, Naohisa

Search repository
Hori, Yukiko

× Hori, Yukiko

WEKO 915399

en Hori, Yukiko

Search repository
Minamimoto, Takafumi

× Minamimoto, Takafumi

WEKO 915400

en Minamimoto, Takafumi

Search repository
抄録
内容記述タイプ Abstract
内容記述 DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) are genetically modified G-protein coupled receptors that are activated by physiologically inert designer drugs. Two types of muscarinic-based designer receptor, such as hM3Dq (excitatory) and hM4Di (inhibitory), are widely used and remotely modulate the neural activity of a target cell population expressing a "designer receptor" by systemic delivery of a designer drug (CNO).
We have shown that positron emission tomography (PET) with [11C]clozapine enables us to monitor the hM4Di expression and the agonist dose–occupancy relationship that provides critical information for successful chemogenetic silencing (Nagai et al., 2016). However, previous designer-drugs suffer from low selectivity and poor metabolic stability.
Here we developed a novel ligand, deschloroclozapine (DCZ), served a dual purpose in chemogenetics: (1) as a selective compound for visualization of DREADD expression in vivo by PET and (2) as a selective agonist for muscarinic-based DREADDs.
会議概要(会議名, 開催地, 会期, 主催者等)
内容記述タイプ Other
内容記述 第6回 CiNet Conference Brain-Machine Interface - Medical Engineering based on Neuroscience -
発表年月日
日付 2020-02-05
日付タイプ Issued
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 17:52:26.305938
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3